International Myeloma Society https://validator.w3.org/feed/docs/rss2.html IMS Connect – April 3, 2026 Home Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE) Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy Targeting inter-organelle communication to arrest multiple myeloma Investigating heme-induced effector CAR T cells for multiple myeloma therapy Comprehensive Exploration of Molecular Pathways and Biomarkers in Myeloma-Induced Bone Disease: A Multi-Omics Approach for Personalized Therapeutic Management iMMagine Dissect the mechanisms by which CST6N137D enhances the efficacy of CAR-T cell therapy in myeloma Targeting Collagen-LAIR1 for Improving Multiple Myeloma Therapeutic Efficacy SHIELD-MM – A modular multiplex shRNA platform to enhance functional persistence of academic anti-BCMA CAR-T cells (ARI0002h) in multiple myeloma. Targeting TCF3 addiction in multiple myeloma Exploiting translation control vulnerabilities imposed by antibody secretion in multiple myeloma Nanobody-based IL-18-armored BCMA/BAFF-R dual-CAR T Cells to Overcome Treatment Failure in Multiple Myeloma Defining the risk of clonal hematopoiesis and therapy-related myeloid neoplasms in multiple myeloma patients receiving ASCT and lenalidomide maintenance ConvAD CART: next-generation BCMA CART cells with modular targeting capacities APOBEC3B as a Biomarker and Therapeutic Vulnerability in TP53-aberrant Multiple Myeloma Correlation between Unfolded Protein Response (UPR) markers and Thrombosis in Multiple Myeloma 4th Annual Workshop on Genomics Uncovering Ferroptosis-Mediated Immune Escape in del(17p) Multiple Myeloma 8th Immune Effector Cell Therapies in Multiple Myeloma Workshop IMS Community Webinar Series: Optimizing the use of ADCs and TCRTs Multimodal investigation of myeloma-recognizing T cells, their transcriptional features and clinical relevance Identify high-risk disease in multiple myeloma through single cell detection of highly proliferative (PR) cells Development of novel extracellular vesicle (EV)/exosome-based treatment for multiple myeloma: therapeutic potential of miR125b-containing osteoblast-derived EVs 23rd Annual Meeting & Exposition Single Year Status – Low and Middle Income Countries Subscribe to IMS Single Year Status – Member-in-Training GLO @IMS Membership Information About Us Renew IMS Membership IMS Connect Member Details/Become a Member Single Year Membership – Associate Member IMS Connect – May 15, 2026 Single Year Membership – Resident, Emeritus and Fellows Two Year Membership Single Year Membership Donate To IMS IMS Connect – April 17, 2026 IMS Connect – May 1, 2026 IMS Connect – April 24, 2026 IMS Connect – May 8, 2026 Meeting Materials West Coast Webinar on NDMM and RRMM – April 2026 East Coast Webinar on NDMM and RRMM – April 2026